The lipid-free structure of apolipoprotein A-I: Effects of amino-terminal deletions

被引:77
作者
Rogers, DP
Roberts, LM
Lebowitz, J
Datta, G
Anantharamaiah, GM
Engler, JA
Brouillette, CG [1 ]
机构
[1] Univ Alabama, Med Ctr, Dept Biochem & Mol Genet, Ctr Macromol Crystallog,Dept Microbiol, Birmingham, AL 35294 USA
[2] Univ Alabama, Med Ctr, Atherosclerosis Res Unit, Birmingham, AL 35294 USA
[3] Calif State Univ Sacramento, Dept Chem, Sacramento, CA 95819 USA
关键词
D O I
10.1021/bi973112k
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Deletion mutants of human apolipoprotein A-I (apo hA-I) have been produced from a bacterial expression system to explore the function of the specific domains comprising residues 1-43, 1-65, 88-98, and 187-243, respectively, in the lipid-free conformation and in the lipid-binding mechanism of apo hA-I. Initial studies on apo Delta(1-43)A-I and apo Delta(187-243)A-I have already been reported. To aid purification of these mutants, a histidine-containing N-terminal extension was incorporated (+his); in cases where comparison with the (-his) construct was possible, little effect on the physical properties due to the (+his) extension was found. All mutants have folded structures in their lipid-free state, however these structures differ widely in their relative thermodynamic stability and extent of secondary structure. The mutant with the fewest residues deleted, apo Delta(88-98)A-I(+his), has the least secondary structure (only 34% helix) and is also the least stable (Delta G = 2.9 kcal/mol). Determined from sedimentation velocity measurements on the lipid-free proteins, all but apo Delta(1-65)A-I(+his) exhibited a range of conformers in solution, which fluctuated around a highly elongated species (dimensions equal to similar to(14-16) x similar to 2.3 nm). Apo Delta(1-65)A-I(+his) exhibited a discrete species which was less asymmetric (dimensions equal to 9 x 2.9 nm). Apo a(88-98)A-I(+his) showed extreme heterogeneity with no predominating conformer, Spectroscopic studies (ANS binding and circular dichroism) indicate that there is little difference in the lipid-free structure of the carboxy-terminal deletion mutant, apo Delta(187-243)A-I(+/-his) compared to wildtype (wt) apo wtA-I(+/-his), but substantial differences are observed between wt and the amino-terminal deletion mutants, apo a(1-43)A-I, apo a(1-65)A-I(+his), and apo Delta(88-98)A-I(+his), In contrast, the lipid-binding properties are impaired for apo Delta(187-243)A-I(+/-his), as measured by dimyristoyl phosphatidylcholine (DMPC) liposome turbidity clearance kinetics and palmitoyloleoyl phosphatidylcholine (POPC) equilibrium binding. Apo Delta(1-43)A-I, apo Delta(1-65)A-I(+his), and apo Delta(88-98)A-I(+his) show lipid affinities statistically similar to apo wtA-I(fhis), but significantly defective DMPC clearance kinetics. Interestingly, lecithin:cholesterol acyltransferase (LCAT) activation results correlate qualitatively with the lipid-binding affinity for all mutants but apo Delta(88-98)A-I(+his), suggesting that this mutant has an altered and possibly noncooperative lipid-bound structure as well as an altered lipid-free structure, These results suggest helix 1 (residues 44-65) and helix 10 (residues 220-240) are both required for native lipid-binding properties, while the presence of internal residues, at least helix 3 (residues 88-98), is essential for proper folding of both the lipid-free and lipid-bound conformations. Importantly, studies on apo a(88-98)A-I(+his) provide the first experimental evidence that a native-like structure is not necessary for native-like lipid affinity, but apparently is necessary for both DMPC solubilization and LCAT activation. These results provide support for a hypothetical, multistep structure-based mechanism for apo hA-I lipid binding.
引用
收藏
页码:11714 / 11725
页数:12
相关论文
共 61 条
[1]  
AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249
[2]  
Albers J J, 1986, Methods Enzymol, V129, P763
[3]   USE OF SYNTHETIC PEPTIDE ANALOGS TO LOCALIZE LECITHIN-CHOLESTEROL ACYLTRANSFERASE ACTIVATING DOMAIN IN APOLIPOPROTEIN-A-I [J].
ANANTHARAMAIAH, GM ;
VENKATACHALAPATHI, YV ;
BROUILLETTE, CG ;
SEGREST, JP .
ARTERIOSCLEROSIS, 1990, 10 (01) :95-105
[4]  
ANANTHARAMAIAH GM, 1988, J LIPID RES, V29, P309
[5]   Pharmacology of apolipoprotein A-I [J].
Andersson, LO .
CURRENT OPINION IN LIPIDOLOGY, 1997, 8 (04) :225-228
[6]   ASYMMETRY OF APOLIPOPROTEIN A-I IN SOLUTION AS ASSESSED FROM ULTRA-CENTRIFUGAL, VISCOMETRIC, AND FLUORESCENCE POLARIZATION STUDIES [J].
BARBEAU, DL ;
JONAS, A ;
TENG, TL ;
SCANU, AM .
BIOCHEMISTRY, 1979, 18 (02) :362-369
[7]   High density lipoproteins and coronary heart disease [J].
Barter, PJ ;
Rye, KA .
ATHEROSCLEROSIS, 1996, 121 (01) :1-12
[8]   Characterization of human apolipoprotein A-I expressed in Escherichia coli [J].
Bergeron, J ;
Frank, PG ;
Emmanuel, F ;
Latta, M ;
Zhao, YW ;
Sparks, DL ;
Rassart, E ;
Denefle, P ;
Marcel, YL .
BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1997, 1344 (02) :139-152
[9]  
BLACKBURN WD, 1991, J LIPID RES, V32, P1911
[10]   Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation [J].
Borhani, DW ;
Rogers, DP ;
Engler, JA ;
Brouillette, CG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (23) :12291-12296